Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation.

Zhao X, Hamidinia M, Choo JAL, Too CT, Ho ZZ, Ren EC, Bertoletti A, MacAry PA, Gould KG, Brzostek J, Gascoigne NRJ.

J Vis Exp. 2019 Feb 28;(144). doi: 10.3791/59126.

2.

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries.

Chen EW, Ke CY, Brzostek J, Gascoigne NRJ, Rybakin V.

J Vis Exp. 2019 Jan 22;(143). doi: 10.3791/58946.

PMID:
30735195
3.

Themis-associated phosphatase activity controls signaling in T cell development.

Mehta M, Brzostek J, Chen EW, Tung DWH, Chen S, Sankaran S, Yap J, Rybakin V, Gascoigne NRJ.

Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):E11331-E11340. doi: 10.1073/pnas.1720209115. Epub 2018 Nov 9.

4.

Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children.

Claeys C, Chandrasekaran V, García-Sicilia J, Prymula R, Díez-Domingo J, Brzostek J, Marès-Bermúdez J, Martinón-Torres F, Pollard AJ, Růžková R, Carmona Martinez A, Ulied A, Miranda Valdivieso M, Faust SN, Snape MD, Friel D, Ollinger T, Soni J, Schuind A, Li P, Innis BL, Jain VK.

Pediatr Infect Dis J. 2019 Feb;38(2):203-210. doi: 10.1097/INF.0000000000002217.

5.

Corrigendum to "One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life" [Vaccine 36 (2018) 381-387].

Henry O, Brzostek J, Czajka H, Leviniene G, Reshetko O, Gasparini R, Pazdiora P, Plesca D, Desole MG, Kevalas R, Gabutti G, Povey M, Innis B.

Vaccine. 2018 Oct 29;36(45):6894. doi: 10.1016/j.vaccine.2018.09.022. Epub 2018 Sep 21. No abstract available.

6.

Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.

Carmona Martinez A, Prymula R, Miranda Valdivieso M, Otero Reigada MDC, Merino Arribas JM, Brzostek J, Szenborn L, Ruzkova R, Horn MR, Jackowska T, Centeno-Malfaz F, Traskine M, Dobbelaere K, Borys D.

Vaccine. 2019 Jan 3;37(1):176-186. doi: 10.1016/j.vaccine.2018.07.023. Epub 2018 Jul 24.

7.

CD8+ T cells have commitment issues.

Balyan R, Brzostek J, Gascoigne NRJ.

Nat Immunol. 2018 Aug;19(8):797-799. doi: 10.1038/s41590-018-0169-0. No abstract available.

PMID:
30013145
8.

Nonstimulatory peptide-MHC enhances human T-cell antigen-specific responses by amplifying proximal TCR signaling.

Zhao X, Sankaran S, Yap J, Too CT, Ho ZZ, Dolton G, Legut M, Ren EC, Sewell AK, Bertoletti A, MacAry PA, Brzostek J, Gascoigne NRJ.

Nat Commun. 2018 Jul 13;9(1):2716. doi: 10.1038/s41467-018-05288-0.

9.

Development of a screening strategy for new modulators of T cell receptor signaling and T cell activation.

Chen EW, Brzostek J, Gascoigne NRJ, Rybakin V.

Sci Rep. 2018 Jul 3;8(1):10046. doi: 10.1038/s41598-018-28106-5.

10.

One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life.

Henry O, Brzostek J, Czajka H, Leviniene G, Reshetko O, Gasparini R, Pazdiora P, Plesca D, Desole MG, Kevalas R, Gabutti G, Povey M, Innis B.

Vaccine. 2018 Jan 8;36(3):381-387. doi: 10.1016/j.vaccine.2017.11.081. Epub 2017 Dec 7. Erratum in: Vaccine. 2018 Oct 29;36(45):6894.

11.

Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.

Sesay S, Brzostek J, Meyer I, Donazzolo Y, Leroux-Roels G, Rouzier R, Astruc B, Szymanski H, Toursarkissian N, Vandermeulen C, Kowalska E, Van Damme P, Salamand C, Pepin S.

Hum Vaccin Immunother. 2018 Mar 4;14(3):596-608. doi: 10.1080/21645515.2017.1384106. Epub 2017 Nov 27.

12.

Seropersistence of TBE virus antibodies 10 years after first booster vaccination and response to a second booster vaccination with FSME-IMMUN 0.5mL in adults.

Konior R, Brzostek J, Poellabauer EM, Jiang Q, Harper L, Erber W.

Vaccine. 2017 Jun 16;35(28):3607-3613. doi: 10.1016/j.vaccine.2017.03.059. Epub 2017 May 22.

PMID:
28545923
13.

A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations.

Wysocki J, Center KJ, Brzostek J, Majda-Stanislawska E, Szymanski H, Szenborn L, Czajka H, Hasiec B, Dziduch J, Jackowska T, Witor A, Kopińska E, Konior R, Giardina PC, Sundaraiyer V, Patterson S, Gruber WC, Scott DA, Gurtman A.

Vaccine. 2017 Apr 4;35(15):1926-1935. doi: 10.1016/j.vaccine.2017.02.035. Epub 2017 Mar 3.

14.

Thymic Origins of T Cell Receptor Alloreactivity.

Brzostek J, Gascoigne NRJ.

Transplantation. 2017 Jul;101(7):1535-1541. doi: 10.1097/TP.0000000000001654. Review.

PMID:
28114168
15.

Antibody persistence and immunologic memory in children vaccinated with 4 doses of pneumococcal conjugate vaccines: Results from 2 long-term follow-up studies.

Wysocki J, Brzostek J, Konior R, Panzer FG, François NA, Ravula SM, Kolhe DA, Song Y, Dieussaert I, Schuerman L, Borys D.

Hum Vaccin Immunother. 2017 Mar 4;13(3):661-675. doi: 10.1080/21645515.2016.1241919. Epub 2016 Oct 13.

16.

TCR Signal Strength and T Cell Development.

Gascoigne NR, Rybakin V, Acuto O, Brzostek J.

Annu Rev Cell Dev Biol. 2016 Oct 6;32:327-348. Review.

PMID:
27712102
17.

SHP1-ing thymic selection.

Gascoigne NR, Brzostek J, Mehta M, Acuto O.

Eur J Immunol. 2016 Sep;46(9):2091-4. doi: 10.1002/eji.201646582.

18.

Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.

Pepin S, Szymanski H, Rochín Kobashi IA, Villagomez Martinez S, González Zamora JF, Brzostek J, Huang LM, Chiu CH, Chen PY, Ahonen A, Forstén A, Seppä I, Quiroz RF, Korhonen T, Rivas E, Monfredo C, Hutagalung Y, Menezes J, Vesikari T.

Hum Vaccin Immunother. 2016 Dec;12(12):3072-3078. doi: 10.1080/21645515.2016.1212143. Epub 2016 Aug 26.

19.

Vive la peptide différence!

Brzostek J, Gascoigne NR.

Nat Immunol. 2016 Jul 19;17(8):896-8. doi: 10.1038/ni.3507. No abstract available.

PMID:
27434001
20.
21.

Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition.

Brzostek J, Gascoigne NR, Rybakin V.

Front Immunol. 2016 Feb 4;7:24. doi: 10.3389/fimmu.2016.00024. eCollection 2016. Review.

22.

Identification of a novel lymphoid population in the murine epidermis.

Almeida FF, Tenno M, Brzostek J, Li JL, Allies G, Hoeffel G, See P, Ng LG, Fehling HJ, Gascoigne NR, Taniuchi I, Ginhoux F.

Sci Rep. 2015 Jul 30;5:12554. doi: 10.1038/srep12554.

23.

Safety, virology and pharmacokinetics of oseltamivir in infants with laboratory-confirmed influenza: a Phase I/II, prospective, open-label, multicentre clinical trial.

Rath BA, Brzostek J, Guillén S, Niranjan V, Chappey C, Rayner CR, Clinch B.

Antivir Ther. 2015;20(8):815-25. doi: 10.3851/IMP2967. Epub 2015 May 27.

PMID:
26015411
24.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.

Wysocki J, Brzostek J, Szymański H, Tetiurka B, Toporowska-Kowalska E, Wasowska-Królikowska K, Sarkozy DA, Giardina PC, Gruber WC, Emini EA, Scott DA.

Vaccine. 2015 Mar 30;33(14):1719-25. doi: 10.1016/j.vaccine.2015.02.005. Epub 2015 Feb 17.

PMID:
25698485
25.

Ligand-engaged TCR is triggered by Lck not associated with CD8 coreceptor.

Casas J, Brzostek J, Zarnitsyna VI, Hong JS, Wei Q, Hoerter JA, Fu G, Ampudia J, Zamoyska R, Zhu C, Gascoigne NR.

Nat Commun. 2014 Nov 27;5:5624. doi: 10.1038/ncomms6624.

26.

Fine-tuning T cell receptor signaling to control T cell development.

Fu G, Rybakin V, Brzostek J, Paster W, Acuto O, Gascoigne NR.

Trends Immunol. 2014 Jul;35(7):311-8. doi: 10.1016/j.it.2014.05.003. Epub 2014 Jun 17. Review.

27.

Themis sets the signal threshold for positive and negative selection in T-cell development.

Fu G, Casas J, Rigaud S, Rybakin V, Lambolez F, Brzostek J, Hoerter JA, Paster W, Acuto O, Cheroutre H, Sauer K, Gascoigne NR.

Nature. 2013 Dec 19;504(7480):441-5. doi: 10.1038/nature12718. Epub 2013 Nov 13.

28.

Too fast to die.

Brzostek J, Gascoigne NR.

Sci Signal. 2013 Oct 15;6(297):pe33. doi: 10.1126/scisignal.2004753.

PMID:
24129699
29.

Coreceptor affinity for MHC defines peptide specificity requirements for TCR interaction with coagonist peptide-MHC.

Hoerter JA, Brzostek J, Artyomov MN, Abel SM, Casas J, Rybakin V, Ampudia J, Lotz C, Connolly JM, Chakraborty AK, Gould KG, Gascoigne NR.

J Exp Med. 2013 Aug 26;210(9):1807-21. doi: 10.1084/jem.20122528. Epub 2013 Aug 12.

30.
31.

Initiation of TCR phosphorylation and signal transduction.

Gascoigne NR, Casas J, Brzostek J, Rybakin V.

Front Immunol. 2011 Dec 7;2:72. doi: 10.3389/fimmu.2011.00072. eCollection 2011.

32.

Matched sizes of activating and inhibitory receptor/ligand pairs are required for optimal signal integration by human natural killer cells.

Köhler K, Xiong S, Brzostek J, Mehrabi M, Eissmann P, Harrison A, Cordoba SP, Oddos S, Miloserdov V, Gould K, Burroughs NJ, van der Merwe PA, Davis DM.

PLoS One. 2010 Nov 5;5(11):e15374. doi: 10.1371/journal.pone.0015374.

33.

Properties and applications of single-chain major histocompatibility complex class I molecules.

Kotsiou E, Brzostek J, Gould KG.

Antioxid Redox Signal. 2011 Aug 1;15(3):645-55. doi: 10.1089/ars.2010.3694. Epub 2011 Mar 31. Review.

34.

Dimerization of soluble disulfide trap single-chain major histocompatibility complex class I molecules dependent on peptide binding affinity.

Kotsiou E, Brzostek J, Lenart I, Antoniou AN, Dyson J, Gould KG.

Antioxid Redox Signal. 2011 Aug 1;15(3):635-44. doi: 10.1089/ars.2010.3691. Epub 2011 Apr 8.

PMID:
21050141
35.

Ligand dimensions are important in controlling NK-cell responses.

Brzostek J, Chai JG, Gebhardt F, Busch DH, Zhao R, van der Merwe PA, Gould KG.

Eur J Immunol. 2010 Jul;40(7):2050-9. doi: 10.1002/eji.201040335.

36.

Modification of the Campylobacter jejuni flagellin glycan by the product of the Cj1295 homopolymeric-tract-containing gene.

Hitchen P, Brzostek J, Panico M, Butler JA, Morris HR, Dell A, Linton D.

Microbiology. 2010 Jul;156(Pt 7):1953-62. doi: 10.1099/mic.0.038091-0. Epub 2010 Mar 25.

37.

Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines.

Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, Borys D, Cleerbout J, Lommel P, Schuerman L.

Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S109-18. doi: 10.1097/INF.0b013e318199f62d. Review.

PMID:
19325447
38.

Membranous structures transfer cell surface proteins across NK cell immune synapses.

Williams GS, Collinson LM, Brzostek J, Eissmann P, Almeida CR, McCann FE, Burshtyn D, Davis DM.

Traffic. 2007 Sep;8(9):1190-204. Epub 2007 Jul 1.

Supplemental Content

Loading ...
Support Center